NSE filing, NSE: DCM. Summary written from the filing by ALFA Finder's alert engine.
DCM Ltd: key numbers
- Share price
- ₹75.81
- Market cap
- ₹141.6 Cr
- Revenue (annual)
- ₹71.78 Cr
- Net profit (annual)
- ₹2.90 Cr
- P/E (TTM)
- 116.1×Sector 51.5×
- Promoter holding
- 50.14%+0.04% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from DCM Ltd
All →DCM Other Announcement
DCM Ltd filed its quarterly shareholding pattern for the quarter ended September 30, 2026, noting the removal of two struck-off promoter group entities.
DCM Annual General Meeting
DCM Limited held its 136th Annual General Meeting on September 28, 2026. Shareholders approved all resolutions, including financial statements and director re-appointments.
DCM Merger & Restructuring
DCM Limited has initiated a voluntary strike-off process for its two non-operational wholly-owned subsidiaries, DCM Realty and Infrastructure Limited and DCM Infinity Realtors Limited.
DCM Other Announcement
DCM Limited dispatched a letter to demat shareholders with unregistered email IDs, providing the web link to access the FY 2025-26 Annual Report.
DCM Annual General Meeting
DCM Limited has issued the notice for its 136th Annual General Meeting scheduled for September 28, 2026, along with the Annual Report for FY 2025-26.
DCM Capital Structure Change
Karan Singh Thakral and PACs acquired 11,250 equity shares of DCM Limited via the open market. This acquisition increases their collective stake to 5.03%.
Other fund raise announcements
All →Sudarshan Pharma Industries Fund Raise of ₹72 Cr
Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.
- Value
- ₹72.00 Cr
Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr
Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.
- Value
- ₹68.20 Cr
Kanel Industries Fund Raise of ₹16.99 Cr
Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.
- Value
- ₹16.99 Cr
- Execution
- Rights issue opens 23 November 2026 and closes 30 November 2026
Sudarshan Pharma Industries Fund Raise
Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.
GAIL (India) Fund Raise
GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.
Gujarat Inject (Kerala) Fund Raise of ₹3 Cr
Gujarat Inject Kerala's board approved a Rs.3 Crore preferential warrant issue to public investors. Authorised capital will rise to Rs.17.63 Crore, subject to shareholder approval.
- Value
- ₹3.00 Cr